img-1
Members in the News

ICIS Member, Dr. John O’Shea, Scientific Director of Intramural Research, Elected to the U.S. National Academy of Sciences

On May 2, 2023, NIAMS Scientific Director of Intramural Research, Dr. John O’Shea, was elected to the U.S. National Academy of Sciences at the conclusion of the Academy’s 160th annual meeting. This designation – considered one of the highest honors that a scientist can achieve – recognizes distinguished and continuing achievements in original research.  [READ MORE]

Christopher Garcia is the 2024 Passano Award winner
Members in the News
ICIS Member and 2019 Milstein Award Winner, Professor Akiko Iwasaki, renowned immunologist, has been named to both the TIME100 and TIME100 Health, two of Time Magazine's lists of the most influential people of 2024. The honor recognizes her pioneering research into post-acute infection syndromes like LlongCOVID.
Members in the News

ICIS Member Akiko Iwasaki has been named to both the TIME100 and TIME100 Health Lists of Most Influential People & in Health in 2024

ICIS Member and 2019 Milstein Award Winner, Professor Akiko Iwasaki, renowned immunologist, has been named to both the TIME100 and TIME100 Health, two of Time Magazine’s lists of the most influential people of 2024. The honor recognizes her pioneering research into post-acute infection syndromes like LongCOVID. [READ MORE]

Georg Schett Courtesy Uniklinikum Erlangen/Simone Kessler—SIMOarts
Members in the News

Georg Schett’s Autoimmunity breakthrough recognized by inclusion in the Time100 Health List of 100 Most Influential People in Health in 2024

Dr. Georg Schett, a world renown rheumatologist at the University Hospital Erlangen in Germany who chaired Cytokines 20219 in Vienna, has been named to Time Magazine’s 100 Most Influential People in Health for 2024 for his work using CAR T therapy to treat Autoimmune Diseases. Dr. Schett saw the potential of new immune-based therapy CAR T which dramatically improved outcomes for patients with certain blood cancers that involve B cells, like leukemia and lymphoma, as a promising treatment for autoimmune diseases like lupus, in which immune B cells attack the body’s own cells. He performed the first CAR T treatments on five patients with the disease in 2022. Eight months after receiving the therapy, all five were in remission and no longer needed powerful immunosuppressive drugs to control their disease. Last year, Schett published a second groundbreaking study showing that another small group of patients receiving the therapy were still in remission more than two years later without immunosuppressive drugs. [READ MORE]

Distinguished Lecturer Christopher A. Hunter’s lecture, From parasites to mRNA vaccines: cytokine networks that dictate T cell tempo
Members in the News
Dr. Brian Kim on the left, and Dr. David Artis on the right at their visit in February to Allen Institute in Seattle, WA. Photo from Dr Kim’s Twitter/X account.
Members in the News

The Tango of Sensation and Inflammation Emerges

Dr. Brian Kim on the left, and Dr. David Artis on the right at their visit in February to Allen Institute in Seattle, WA. Photo from Dr Kim’s Twitter/X account.

Some dermatological disorders such as atopic dermatitis, alopecia areater, and vitiligo have few treatments available due to the lack of effective medications currently on the market. However, this might change soon with the formation of a new biotech entity called Alys Pharmaceuticals, Inc. that launched on 12th of February. It started with a substantial 100-million-dollar investment from Medicxi, the European healthcare investment fund, with the goal of transforming the treatment paradigm for several dermatology indications of significant prevalence and major unmet need. Alys, based in Boston and Geneva, is the combination of the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics, and has a world class leadership team that brings together experts across dermatology and advanced scientific fields. [READ MORE]

img-7
Members in the News

Congratulations to Thirumala-Devi Kanneganti 2024 AAI-Thermo Fisher Meritorious Career Award

Congratulations ICIS member and former Council Member, Thirumala-Devi Kanneganti, PhD, for being awarded the 2024 AAI-Thermo Fisher Meritorious Career Award for her research identifying fundamental mechanisms and establishing new scientific paradigms connecting innate immunity, cell death, and disease. [READ MORE]

The first Global Immunocourse, a sister initiative of Global Immunotalks, was held in IISc, Bengaluru. Global Immunotalks is an online, archived seminar series available on YouTube, featuring preeminent immunologists (www.globalimmunotalks.org).
Members in the News

ICIS Council Member Carla Rothlin Takes the Global ImmunoCourse to India

The first Global ImmunoCourse, a sister initiative of Global Immunotalks, was held in IISc, Bengaluru. Global Immunotalks is an online, archived seminar series available on YouTube, featuring preeminent immunologists (www.globalimmunotalks.org). Global ImmunoCourse is designed to introduce the fundamentals of immunology in an engaging manner and foster a global community of passionate [READ MORE]

img-9
Members in the News
img-10
Members in the News